{
  "paper_metadata": {
    "pmid": "37655225",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": "p.Val50Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 42,
        "demographics": "not specified",
        "phenotype": "ATTRv amyloidosis with varying clinical presentations"
      },
      "penetrance_data": {
        "total_carriers_observed": 10,
        "affected_count": 4,
        "unaffected_count": 6,
        "uncertain_count": null,
        "penetrance_percentage": 40.0,
        "age_dependent_penetrance": [
          {
            "age_range": "40-50 years",
            "penetrance_percentage": null,
            "carriers_in_range": null,
            "affected_in_range": null
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "early-onset disease with small-fiber neuropathy",
          "evidence_sentence": "the predominant genotype, Val50Met (V50M), is responsible for ATTRv amyloidosis in endemic foci, where it is typically associated with early-onset disease (age < 50 years)"
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "no symptoms reported",
          "evidence_sentence": "In contrast, in non-endemic areas, patients with the V50M variant usually have late-onset disease (age \u2265 50 years) with more severe motor neuropathy"
        }
      ],
      "functional_data": {
        "summary": "The V50M variant is associated with a neurological phenotype and has been linked to disease severity.",
        "assays": []
      },
      "segregation_data": "Yes, it segregates with disease in families.",
      "population_frequency": "not specified",
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The V50M variant is the most common and has significant implications for disease progression and treatment outcomes.",
      "key_quotes": [
        "the 5-year post-OLT survival rate has been reported to be approximately 100% for V50M patients and 59% for non-ATTR V50M patients."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.74G>A",
      "protein_notation": "p.Glu74Gly",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 2,
        "demographics": "not specified",
        "phenotype": "neuropathy and autonomic dysfunction"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "progressive sensorimotor neuropathy",
          "evidence_sentence": "a post-OLT patient with the Glu74Gly variant experienced a continued worsening of sensorimotor neuropathy despite tafamidis treatment"
        }
      ],
      "functional_data": {
        "summary": "The Glu74Gly variant has been associated with worsening neuropathy despite treatment.",
        "assays": []
      },
      "segregation_data": "Not specified.",
      "population_frequency": "not specified",
      "evidence_level": "moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The variant's impact on treatment response highlights its clinical significance.",
      "key_quotes": [
        "the Glu74Gly patient improved after switching from tafamidis to patisiran."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 2",
      "table_caption": "Characteristics and clinical outcomes of patients who underwent OLT at Bellvitge University Hospital from January 1997 to August 2019.",
      "variants_extracted": 2
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data for TTR variants were extracted from the main text and tables."
  }
}